Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Nicolas Floc’h(AstraZeneca (United Kingdom)), Darren A.E. Cross(AstraZeneca (United Kingdom)), Anna D. Staniszewska(AstraZeneca (United Kingdom)), Ludovic Ménard(AstraZeneca (United Kingdom)), Rebekah A. Burich(UC Davis Comprehensive Cancer Center), M. Raymond V. Finlay(AstraZeneca (United Kingdom)), Maria Emanuela Cuomo(AstraZeneca (United Kingdom)), James Keck(Jackson Laboratory), David R. Gandara(University of California, Davis), Darren McKerrecher(AstraZeneca (United Kingdom)), Matthew J. Martin(Stony Brook University Hospital), Mingshan Cheng(Jackson Laboratory), Jonathan P. Orme(AstraZeneca (United Kingdom)), Jonathan W. Riess(University of California Davis Medical Center), Richard A. Ward(AstraZeneca (Poland)), Daniel P. Vang(University of California, Davis), Daniel O’Neill(AstraZeneca (United Kingdom)), Philip C. Mack(UC Davis Comprehensive Cancer Center)
Cited by 113
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k